Fresenius submits biosimilar Marketing Authorization Application

Medium_fresenius-kabi

Fresenius Kabi submitted its first biosimilar regulatory Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. 

Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.

Read more >>

 

Return to Pharma News